• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by EQRx Inc.

    2/11/22 4:57:41 PM ET
    $EQRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EQRX alert in real time by email
    SC 13G 1 arch-sch13g_18587.htm ARCH VENTURE FUND X, L.P. - EQRX, INC. -- SCH 13G

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

      (Amendment No.    )*

     

     

     

    EQRx, Inc.

    (Name of Issuer)

       

    Common Stock par value $0.0001 per share

     

    (Title of Class of Securities)

      

    26886C107

     

    (CUSIP Number)

      

    December 31, 2021

     

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐   Rule 13d-1(b)

    ☐   Rule 13d-1(c)

    ☒   Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

    CUSIP No.  26886C107

    13G Page 2 of 16 Pages    

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Fund X, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    36,335,375

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    36,335,375

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    36,335,375

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    7.5%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    PN

     

       

     
     

     

    CUSIP No.  26886C107

    13G Page 3 of 16 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Fund X Overage, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    36,335,375

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    36,335,375

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    36,335,375

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    7.5%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    PN

     

       

     
     

    CUSIP No.  26886C107

    13G Page 4 of 16 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Partners X, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    36,335,375

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    36,335,375

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    36,335,375

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    7.5%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    PN

     

       

     
     

    CUSIP No.  26886C107

    13G Page 5 of 16 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Partners X Overage, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    36,335,375

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    36,335,375

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    36,335,375

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    7.5%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    PN

     

       

     
     

    CUSIP No.  26886C107

    13G Page 6 of 16 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Partners X, LLC

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    36,335,375

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    36,335,375

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    36,335,375

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    7.5%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    OO

     

       

     
     

    CUSIP No.  26886C107

    13G Page 7 of 16 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    Keith Crandell

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    36,335,375

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    36,335,375

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    36,335,375

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    7.5%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    IN

     

       

     
     

    CUSIP No.  26886C107

    13G Page 8 of 16 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    Kristina Burow

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    36,335,375

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    36,335,375

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    36,335,375

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    7.5%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    IN

     

       

     
     

    CUSIP No.  26886C107

    13G Page 9 of 16 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    Steven Gillis

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    36,335,375

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    36,335,375

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    36,335,375

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    7.5%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    IN

     

       

     
     

    CUSIP No.  26886C107

    13G Page 10 of 16 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    Robert Nelsen

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    36,335,375

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    36,335,375

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    36,335,375

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    7.5%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    IN

     

       

     
     

    CUSIP No.  26886C107

    13G Page 11 of 16 Pages    

     

     

    Item 1(a). Name of Issuer:

     

    EQRx, Inc. (the “Issuer”).

     

     

    Item 1(b). Address of Issuer's Principal Executive Offices:

     

    50 Hampshire Street, Cambridge, MA 02139

     

     

    Item 2(a). Name of Person Filing:

     

    ARCH Venture Fund X, L.P. (“AVF X”); ARCH Venture Partners X, L.P. (“AVP X LP”); ARCH Venture Partners X, LLC (“AVP X LLC”); ARCH Venture Fund X Overage, L.P. (“AVF X Overage”); ARCH Venture Partners X Overage, L.P. (“AVF X Overage GP”) (collectively, the “Reporting Entities” and individually, each a “Reporting Entity”); and Keith Crandell (“Crandell”), Robert Nelsen (“Nelsen”), Kristina Burow (“Burow”) and Steven Gillis (“Gillis) (collectively, the “Investment Committee” and individually, each a “Committee Member”). The Reporting Entities and the Committee Members collectively are referred to as the “Reporting Persons”. 

     

     

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     

    8755 W. Higgins Avenue, Suite 1025, Chicago, IL 60631

     

     

    Item 2(c). Citizenship:

     

    Each of AVF X, AVF X LP, AVF X Overage and AVP X Overage GP, are limited partnerships organized under the laws of the State of Delaware. AVP X LLC is a limited liability company organized under the laws of the State of Delaware. Each Committee Member is a US citizen.

     

     

    Item 2(d). Title of Class of Securities.

     

    Common stock, par value $0.0001 per share.

     

     

    Item 2(e). CUSIP Number.

     

    26886C107

     

      

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    Not Applicable.

     

     
     

    CUSIP No.  26886C107

    13G Page 12 of 16 Pages    

     

    Item 4. Ownership:

     

    (a)

    Amount beneficially owned:

     

    AVF X is the record owner of 18,167,688 shares of Common Stock (the “AVF X Shares”) as of December 31, 2021. AVP X LP, as the sole general partner of ARCH Venture Fund X, may be deemed to beneficially own the AVF X Shares. AVF X Overage is the record owner of 18,167,687 shares of Common Stock (the “AVF X Overage Shares”; combined with AVF X Shares, the “Record Shares”) as of December 31, 2021. AVF X Overage GP, as the sole general partner of AVF X Overage, may be deemed to beneficially own the AVF X Overage Shares. AVP X LLC, as the sole general partner of AVP X LP and AVF X Overage GP, may be deemed to beneficially own the Record Shares. As Committee Members of AVP X LLC, each Committee Member may also be deemed to share the power to direct the disposition and vote of the Record Shares.

     

    (b)

    Percent of class:

     

    See line 11 of the cover sheets. The percentages set forth on the cover sheet for each Reporting Person is based upon 487,632,615 shares of common stock outstanding as of December 17, 2021 as reported on the Issuer’s Form 424B3 as filed with the Securities and Exchange Commission on December 23, 2021.

       
    (c) Number of shares as to which such person has:

      (i)

    Sole power to vote or to direct the vote:

     

    See line 5 of the cover sheets.

         
      (ii)

    Shared power to vote or to direct the vote:

     

    See line 6 of the cover sheets.

         
      (iii)

    Sole power to dispose or to direct the disposition:

     

    See line 7 of the cover sheets.

         
      (iv)

    Shared power to dispose or to direct the disposition:

     

    See line 8 of the cover sheets.

         

    Each Reporting Person disclaims beneficial ownership of such shares of Common Stock except for the shares, if any, such Reporting Person holds of record.

     

    Item 5. Ownership of Five Percent or Less of a Class.

    Not applicable.

     

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

     

    Item 10. Certifications.

     

    Not applicable.

      

     
     

    CUSIP No.  26886C107

    13G Page 13 of 16 Pages    

     

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:    February 11, 2022

    ARCH VENTURE FUND X, L.P.

     

    By:       ARCH Venture Partners X, L.P.

    its General Partner

     

    By:       ARCH Venture Partners X, LLC

    its General Partner

     

    By:                    *                   

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS X, L.P.

     

    By:       ARCH Venture Partners X, LLC

    its General Partner

     

    By:                           *                        

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS X, LLC

     

    By:                                *                                

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE FUND X OVERAGE, L.P.

     

    By:       ARCH Venture Partners X Overage, L.P.

    its General Partner

     

    By:       ARCH Venture Partners X, LLC

    its General Partner

     

    By:                    *                   

    Keith Crandell

    Managing Director 

     

     

    ARCH VENTURE PARTNERS X OVERAGE, L.P.

     

    By:       ARCH Venture Partners X, LLC

    its General Partner

     

    By:                    *                   

    Keith Crandell

    Managing Director

     

     

     
     

    CUSIP No.  26886C107

    13G Page 14 of 16 Pages    

     

     

     

     

     

     

                                          *                                 

    Keith Crandell

     

     

                                          *                                 

    Robert Nelsen

     

     

                                          *                                 

    Kristina Burow

      

     

                                          *                                 

    Steven Gillis

     

     

     

     

     

     

     

     

     

     

    * By:   /s/ Mark McDonnell                  

    Mark McDonnell as

    Attorney-in-Fact

     

     

    *       This Schedule 13D was executed by Mark McDonnell pursuant to Powers of Attorney filed as Exhibit 24 and 24.1 to the Form 3 relating to the beneficial ownership of shares of Verve Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission on June 16, 2021 and incorporated herein in its entirety by reference.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     
     

    CUSIP No.  26886C107

    13G Page 15 of 16 Pages    

     

     

    Exhibit 1

     

    AGREEMENT

     

    Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of EQRx, Inc.

     

    This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

     

     

    Dated:    February 11, 2022

    ARCH VENTURE FUND X, L.P.

     

    By:       ARCH Venture Partners X, L.P.

    its General Partner

     

    By:       ARCH Venture Partners X, LLC

    its General Partner

     

    By:                    *                   

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS X, L.P.

     

    By:       ARCH Venture Partners X, LLC

    its General Partner

     

    By:                           *                        

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS X, LLC

     

    By:                               *                                

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE FUND X OVERAGE, L.P.

     

    By:       ARCH Venture Partners X Overage, L.P.

    its General Partner

     

    By:       ARCH Venture Partners X, LLC

    its General Partner

     

    By:                    *                   

    Keith Crandell

    Managing Director 

     

     

    ARCH VENTURE PARTNERS X OVERAGE, L.P.

     

    By:       ARCH Venture Partners X, LLC

    its General Partner

     

    By:                    *                   

    Keith Crandell

    Managing Director

     

     
     

    CUSIP No.  26886C107

    13G Page 16 of 16 Pages    

     

     

     

     

     

     

     

     

                                          *                                 

    Keith Crandell

     

     

                                          *                                 

    Robert Nelsen

     

     

                                          *                                 

    Kristina Burow

      

     

                                          *                                 

    Steven Gillis

     

     

     

     

     

     

     

     

     

    * By:   /s/ Mark McDonnell                  

    Mark McDonnell as

    Attorney-in-Fact

     

     

    *             This Agreement was executed by Mark McDonnell pursuant to Powers of Attorney filed as Exhibit 24 and 24.1 to the Form 3 relating to the beneficial ownership of shares of Verve Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission on June 16, 2021 and incorporated herein in its entirety by reference.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $EQRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EQRX

    DatePrice TargetRatingAnalyst
    11/14/2022Neutral → Underweight
    JP Morgan
    11/11/2022$8.00 → $5.00Buy → Neutral
    Goldman
    11/11/2022$5.60 → $3.20Buy → Hold
    Jefferies
    8/16/2022$5.50Neutral
    JP Morgan
    6/13/2022$8.00Buy
    Goldman
    4/22/2022Outperform
    Cowen
    3/18/2022$5.60Buy
    Jefferies
    More analyst ratings

    $EQRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lifshitz Law PLLC Announces Investigations of EQRX, RVMD, NEWR, and RETA

      NEW YORK, Aug. 05, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of EQRX to Revolution Medicines, Inc. Under the terms of the proposed merger, EQRX shareholders will receive the number of shares of Revolution Medicines, Inc. stock equal to the sum of ~7.69M Revolution Medicines, Inc. shares plus a number of shares equal to $870M divided by a price that is a 6% discount to the 5-day volume-weighted average Revolution Medicines Inc. share price measured in close proximity to the stockholder vote. If you are an EQRX investor, and would like additional information abo

      8/5/23 8:13:00 PM ET
      $EQRX
      $NEWR
      $RETA
      $RVMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Computer Software: Prepackaged Software
      Technology
    • Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

      Revolution Medicines Expects to Conduct Late-Stage Development of RAS(ON) Inhibitor Drug Candidate Pipeline Supported by Fortified Balance Sheet Agreement is the Result of a Rigorous Process Conducted by Independent Transaction Committee of EQRx Board to Consider Strategic Alternatives to Maximize Value for EQRx Stockholders Transaction Expected to Close in November 2023 REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ("Revolution Medicines" or the "Company") (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. ("EQRx") (NASDAQ:EQRX) today announced a definitive agr

      8/1/23 7:00:00 AM ET
      $EQRX
      $RVMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results

      Company to utilize significant scale of capital and team to advance a pipeline of clinically differentiated, high-value therapiesPrioritizing development of lerociclib (CDK 4/6 inhibitor); initiated Phase 3 trial in first-line advanced endometrial cancer; enrollment in Phase 2 trial in first- and second-line advanced breast cancer near completion, providing a foundation for future combination development opportunitiesSeeking commercialization partnerships for aumolertinib (third-generation EGFR inhibitor)Terminating license agreements for sugemalimab (anti-PD-L1 antibody), nofazinlimab (anti-PD-1 antibody) and EQ121 (JAK-1 inhibitor)$1.3 billion in cash, cash equivalents and short-term inves

      5/8/23 4:01:57 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Nallicheri Melanie returned 10,157,393 shares to the company and exercised 626,999 shares at a strike of $2.21, closing all direct ownership in the company (SEC Form 4)

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:27:28 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Merksamer Samuel J.

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:18:02 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berns Paul L returned 627,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - EQRx, Inc. (0001843762) (Issuer)

      11/9/23 4:18:04 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EQRx downgraded by JP Morgan

      JP Morgan downgraded EQRx from Neutral to Underweight

      11/14/22 7:36:09 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EQRx downgraded by Goldman with a new price target

      Goldman downgraded EQRx from Buy to Neutral and set a new price target of $5.00 from $8.00 previously

      11/11/22 9:09:51 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EQRx downgraded by Jefferies with a new price target

      Jefferies downgraded EQRx from Buy to Hold and set a new price target of $3.20 from $5.60 previously

      11/11/22 7:14:21 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQRX
    Financials

    Live finance-specific insights

    See more
    • Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

      Revolution Medicines Expects to Conduct Late-Stage Development of RAS(ON) Inhibitor Drug Candidate Pipeline Supported by Fortified Balance Sheet Agreement is the Result of a Rigorous Process Conducted by Independent Transaction Committee of EQRx Board to Consider Strategic Alternatives to Maximize Value for EQRx Stockholders Transaction Expected to Close in November 2023 REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ("Revolution Medicines" or the "Company") (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. ("EQRx") (NASDAQ:EQRX) today announced a definitive agr

      8/1/23 7:00:00 AM ET
      $EQRX
      $RVMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results

      Company to utilize significant scale of capital and team to advance a pipeline of clinically differentiated, high-value therapiesPrioritizing development of lerociclib (CDK 4/6 inhibitor); initiated Phase 3 trial in first-line advanced endometrial cancer; enrollment in Phase 2 trial in first- and second-line advanced breast cancer near completion, providing a foundation for future combination development opportunitiesSeeking commercialization partnerships for aumolertinib (third-generation EGFR inhibitor)Terminating license agreements for sugemalimab (anti-PD-L1 antibody), nofazinlimab (anti-PD-1 antibody) and EQ121 (JAK-1 inhibitor)$1.3 billion in cash, cash equivalents and short-term inves

      5/8/23 4:01:57 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023

      CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (NASDAQ:EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced it will host a conference call and webcast on Monday, May 8, 2023, at 4:30 p.m. ET to report its first quarter 2023 financial results and provide a business update. A live webcast of the call will be available on the "Investor Relations" page of the Company's website at https://investors.eqrx.com/news-events/events-presentations. To access the call by phone, participants should visit this link

      4/27/23 8:00:34 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by EQRx Inc. (Amendment)

      SC 13G/A - EQRx, Inc. (0001843762) (Subject)

      11/17/23 4:23:37 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by EQRx Inc. (Amendment)

      SC 13D/A - EQRx, Inc. (0001843762) (Subject)

      11/17/23 6:00:34 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by EQRx Inc. (Amendment)

      SC 13D/A - EQRx, Inc. (0001843762) (Subject)

      11/15/23 5:27:53 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EQRX
    SEC Filings

    See more
    • SEC Form 15-12G filed by EQRx Inc.

      15-12G - EQRx, Inc. (0001843762) (Filer)

      11/20/23 4:00:52 PM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by EQRx Inc.

      EFFECT - EQRx, Inc. (0001843762) (Filer)

      11/20/23 12:15:18 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by EQRx Inc.

      EFFECT - EQRx, Inc. (0001843762) (Filer)

      11/20/23 12:15:12 AM ET
      $EQRX
      Biotechnology: Pharmaceutical Preparations
      Health Care